Passage BIO, Inc. (NASDAQ: PASG)

Passage BIO, Inc. (PASG) operates in the genetic medicines industry, specializing in the development of cutting-edge, one-time gene therapies that target the underlying pathology of neurodegenerative diseases. The company's primary focus is on central nervous system (CNS) disorders, with a particular emphasis on frontotemporal dementia (FTD) and other neurodegenerative diseases.

Passage BIO's main business activities revolve around the discovery, development, and advancement of treatments for CNS disorders. They collaborate with renowned research institutions and leverage their robust manufacturing capabilities to drive the development of new treatments for patients with these diseases. The company has a research collaboration with the University of Pennsylvania's Gene Therapy Program (GTP), led by Dr. James Wilson, and a license agreement with Penn for patients with amyotrophic lateral sclerosis (ALS) who have a gain-of-function mutation in the C9orf72 gene. Additionally, they have a program under their exploratory research program with GTP for Temporal Lobe Epilepsy (TLE).

Revenue for Passage BIO is generated through the development of their genetic medicine product candidates, with a focus on neurodegenerative diseases. Their primary product, PBFT02, is a gene therapy designed to elevate progranulin levels to restore lysosomal function and slow disease progression across various neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus (AAV1) capsid to deliver a functional granulin gene to the brain via intra-cisterna magna administration. The company is currently studying PBFT02 in a Phase 1/2 clinical trial for the treatment of FTD caused by progranulin deficiency.

Passage BIO holds a strong competitive position within the industry, thanks to its proprietary technology, manufacturing know-how, and intellectual property portfolio. They have filed two patent applications on new methods to improve the manufacturing of their products. The company's competitive advantages lie in their ability to develop and maintain a strong intellectual property portfolio and their partnerships with institutions such as the University of Pennsylvania.

Their product candidates are subject to regulation by the FDA and other regulatory authorities, requiring compliance with various statutes, regulations, and guidelines. Passage BIO's manufacturing capabilities provide the company with better control of drug development timelines, improved control of vector supply for a portfolio of clinical assets, and improved control of product quality.